Foto del docente

Giovanni Brandi

Associate Professor

Department of Experimental, Diagnostic and Specialty Medicine - DIMES

Academic discipline: MED/06 Medical Oncology

Head of Scuola di Specializzazione Oncologia Medica (DI 68/2015)

Curriculum vitae

Giovanni Brandi

Born in Urbania (PU, Italy), 20/03/1955

 

Academic and professional qualifications

  • Graduated in the Bologna University Medical School with honors (110/110 cum laude) in 1988.
  • Licensed to practice as MD in the Bologna University Medical School in the first session of 1988
  • Enrollment in the Bologna professional list of Physicians and Surgeons since 05/21/1988, No 12489
  • Specialization in Internal Medicine (70/70 cum laude) in 1996.
  • PhD in "Biological Markers of tumors of the gastrointestinal tract" in 1992 with a thesis entitled "Abnormal cell proliferation as a marker of risk of rectal cancer of the large intestine"
  • In 1991 Six month stage at the INRA in the “Unitè de Physiologie et D'Ecologie du Système Digestif”, Jouy en Josas, Paris, to study the problems of the intestinal microbiota in relation to preneoplastic diseases of the gastrointestinal tract and to learn the techniques of analysis of the gut microbiota using germ-free animal models and gnotobiotic (ex germ-free associated to known flora) applied to various diseases of the gastrointestinal tract.
  • One month stage about cronomodulation for the study of tumors at the Service of Medical Oncology “Paul Brousse”, Villejuif (Paris), directed by Dr. Francis Levi, in 1996.
  • Medical Assistant of Internal Medicine in the Cesena hospital from 13/03/2000 to 31/12/2000.
  • Researcher of Medical Oncology in the department of Hematology and Oncological Sciences of the Bologna University Medical School from 01/01/2001 to 31/10/2010.
  • Associate Professor of Medical Oncology in the department of Hematology and Oncological Sciences of the Bologna University Medical School from 01/11/2010 to present.

  

Institutional roles

  • Member of the Collegio Superiore of the University of Bologna (from November 2002 to present);
  • Member of the Board of I.S.A. (Institute of Advanced Studies) of the University of Bologna (from February 2013 to present);
  • Member of the Board of I.S.S (Institute of Superior Studies) of the University of Bologna (from November 2008 to present)
  • Member of the Board of CINBO  (National interuniversity board for the Biotechnology) from 20/1/2014 to present
  • Member of the Board of CIRC (Interdepartmental centre for cancer research “G. Prodi” from 2001 to present
  • Member of CRBA of the University of Bologna from 2010 to present
  • Referent Professor (University of Bologna) in the bilateral LL / ERASMUS agreements with the Semmelweis University (Hungary) and the University Medical School in Poznan (Poland) (from November 2012 to the present)
  • Director of the Specialization School in Medical Oncology in Bologna from December 2010 to November 2013;
  • Director of second level Master in Training and Qualification in Palliative Care from July 2012 to present, sponsored by Isabella Seragnoli-Hospice Foundation and University of Bologna.
  • President of Gruppo Italiano Colangiocarcinoma- GICO

 

Teaching  Activities

  • Professor in the School of Specialization in Medical Oncology at the University of Bologna since 2002
  • Professor of Medical Oncology since 2013 in the Schools of Specialization in: Medical Physics,  Thoracic Surgery , Food Science
  • Professor of Medical Oncology in the Bologna University Medical School as Professor of the course "Fundamentals in Oncology " for the three-year course of "Technicians of Medical Radiology and Radiotherapy " from 2004 to 2013; Professor of " Medical Oncology " in the integrated courses of " Medical Sciences 4 " (from 2004 to 2013) and " Medical Sciences 3 " (2013 -14) for the master in Dietetic Science .
  • Professor of the PhD in " Oncology, Methodology and Pathology " of the University of Bologna since February 2014
  • Professor at the Collegio Superiore of the University of Bologna since 2002 (seminars and tutoring)

 

Membership

  • Global Translational Medicine Consortium (GTMC), that is part of the The European Society for Translational Medicine (EUSTM)
  • AlmaSeq dell'Università di Bologna
  • Bologna Liver Oncology Group (BLOG)
  • Advisory Board – AstraZeneca (Selumetinibin BiliaryTract Cancer)
  • Clinical Responible for Nanotarget (Barcellona start up of nanotechnology dedicated to the creation of oncology drugs conveyed with nanogold)
  • American Society of Clinical Oncology (ASCO)
  • Member of the “Dyonisos Projet Group" epidemiological research project on liver disease (1991-1996)

 

Peer review activities and editorial board:
  • Reviewer for: NEJM (8 times from 2008 to 2013: articles on hepatocarcinogenesis or treatment of HCC), Eur J Cancer; PlosOne; Cancer Letter; Chemotherapy; J of Chem; Thromb Hemost; Int J of Cancer, Oncology, Nat Clin Pract Gastroent, Indian Journal of Medicine, Cancer.
  • Member of editorial board of “Chinese Journal of Clinicians” (International) and “Journal of Hematology and Thromboembolic Diseases”, “Journal of Gastro: Open Access”, “Medicines”.
  • In 2002, on behalf of the European Commission, the Italian government and University of Bologna, he was evaluator for the European funding of 700 projects of universities and scientific research centres in Serbia. Reviewer of the oncologic projects pertaining.
  •  In 2006, evaluator of the INSERM (France) project : "Environmental factors and gastrointestinal carcinogenesis" 01EUEA_ scientific Project, PI Prof Iradj Sobhani.

Publications and congress activity

The writer is author of  more than 100 papers in international journals indexed (with IF> 500), 6 scientific books, 9 book chapters, and he has been speaker and chairman at national and international conferences 

 Awards

 • For the book : " Ultrastructure microbienne Ecologie et du Tube Digestif Humain " G Brandi , AM Flats , G Biasco, awarded in France during the Ninth Edition of the International Scientific Paper (Deauville, Normandy 5 to 7 June 1998) as the best work dedicated to continuing medical education .

 • PI of the poster : " Occupational exposure to asbestos : a putative unknown risk factors for intrahepatic cholangiocarcinoma " ILCA , Hong Kong , 2011 (ILCA Junior Investigator Award, given to the co-author dr. S. Di Girolamo)

 International collaborations

  •  2012 – to present: collaboration with the institute INRA , Jouy en Josas , and the Hospital Saint Antoine, Paris (France) ( Dr. P. Langella , Dr. Henry Sokol ) for the study of intestinal microbiota in the genesis of colorectal cancer
  • 2012 – to present: collaboration with CIRM in Marseille, France (Prof. G. Chapuisat and Prof. P. Sicbaldi ), for the creation of mathematical models of standardization of therapeutic strategies in patients with advanced carcinoma of the colon .
  •  2013 – to present: collaboration with the cancer registry of northern Europe (NOCCA) in particular with Professor Eeron Pukkala, to evaluate the role of asbestos in carcinogenesis of the biliary tract
  • 2013 – to present: Collaboration with Mayo Clinic (Rochester , USA ), Cornell University (NY , USA), Christie Hospital (Manchester, UK), Tokio University and Singapore University, for writing the book " Cholangiocarcinoma " - Nova Science Publisher, New York , planned publication in October 2014 (Giovannii Brandi & Giorgio Ercolani editors).

 

Responsibility for scientific research projects funded on the basis of competitive calls

 • 2000 - Young Researchers UNIBO : "Role of the human intestinal microflora in the toxicity induced by CPT-11 using germ-free mice and eteroxenic model " ( 7.5 million pounds ) (12 months , PI)

• 2003 - FIRB : "Design and synthesis of new radiopharmaceuticals for molecular recognition of onco - hematological and endocrine-metabolic pathologies using high-throughput imaging method in vivo (micro- PET) (share Unit  : EUR 228,000 ) ( 36 months duration , co -PI of units)

• 2005 - PRIN : " Liver metastases from colorectal cancer : risk factors, prognosis, and treatment on molecular basis " ( 87 143 euro ) ( 36 months duration , co -PI of units)

• 2006/2012- RFO Unibo ( total amount of EUR 59 520 ) (one-year programs, PI)

• 2010-2012 - Region - University Program: "Innovative approaches to the diagnosis and pharmacogenetic - based therapies of primary hepatic Tumours , peripheral B and T -cell lymphoblastic lymphomas and leukaemias " ( 75.000 € ) ( 36 months duration , co- PI of Work Pakage 3 and 4)

• 2013 – Del Monte Foundation: "Searching for genetic markers of asbestos exposure in patients with intrahepatic cholangiocarcinoma using next generation sequencing technology " (€ 23,000 ) (12 months , PI)

 

 Areas of Clinical Activities and Management

The writer is devoted to care activities as part of the agreement between the University of Bologna and S. Orsola -Malpighi Hospital as the medical staff of the NHS : Medical Doctor from 01.01.2002 to present.

The activity of the medical oncologist has been always carried out as part of the " Biasco" Unit.

Here (as certified by the head of the Unit) conducted exclusively the activity of DH and ambulatory of general oncology until the end of 2006, since then he has integrated it with the the care of specifically selected patients with primary and secondary liver tumors, seeing about 60 new HCC, 50 cholangiocarcinomas , 40 liver metastases from colorectal cancer and about 20 NET per year. He dedicate a portion of its activity also to neoplasia of the pancreas, in collaboration with other colleagues in the Unit.

This clinical activity takes place in complete harmony with the other structures of the Hospitals, primarily surgeries ( hepatobiliary and colorectal ) , the interventional radiology , pathologists and radiotherapists . Interesting to note that the management of the epatobiliopancreatic disease and transplantation is one of the strategic areas of the S. Orsola -Malpighi Hospital.

In addition, since 2004, first as secretary and then as Director of the School of Specialization in Medical Oncology (November 2010 - November 2013), he was devoted to training and managing activities of dozens of young oncologists. In this perspective, the writer has tried to teach the younger colleagues a method of scientific and clinical reasoning that would allow them to cope with the rapid changes in the future of medical oncology. The fact that most of our former interns have easily found a job and that their skills are widely appreciated in the structures in which they currently operate, supports the vitality of our graduate school. It has also been recognized by the region that for the academic year 2013-2014 has funded an extra scholarship.

The writer has also involved the interns in drafting the book " Follow-up in Oncology " for the  Bologna University Press, that will be published in the coming months.

 

PUBLICATIONS:

Prevalence of and risk factors for hepatic steatosis in Northern Italy S Bellentani, G Saccoccio, F Masutti, LS Crocè… - Annals of internal medicine, 2000

The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses V Gaboriau-Routhiau, S Rakotobe, E Lécuyer, I Mulder… - Immunity, 2009 

Drinking habits as cofactors of risk for alcohol induced liver damage S Bellentani, G Saccoccio, G Costa, C Tiribelli… - Gut, 1997

High prevalence of celiac disease in Italian general population U Volta, S Bellentani, FB Bianchi, G Brandi… - Digestive diseases and sciences, 2001

Interactions between commensal bacteria and gut sensorimotor function in health and diseaseG Barbara, V Stanghellini, G Brandi, C Cremon… - The American journal of gastroenterology, 2005 

Effect of vitamin A, C, and E supplementation on rectal cell proliferation in patients with colorectal adenomas GM Paganelli, G Biasco, G Brandi, R Santucci, G Gizzi… - Journal of the National Cancer Institute, 1992 

Hypersensitivity reactions related to oxaliplatin (OHP) G Brandi, MA Pantaleo, C Galli, A Falcone… - British journal of cancer, 2003 

Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties          G Biasco, E Derenzini, GL Grazi, G Ercolani, M Ravaioli… - Cancer treatment reviews, 2006 

Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment?(Review)        M Di Marco, R Di Cicilia, M Macchini, E Nobili… - Oncology reports, 2010 

Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival G Ercolani, G Vetrone, GL Grazi, O Aramaki, M Cescon… - Annals of surgery, 2010

Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia M Renga,  G Brandi, GM Paganelli, C Calabrese… - Gut, 1997 

Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention D Colussi, G Brandi, F Bazzoli, L Ricciardiello - International journal of molecular

sciences, 2013 

Effect of lactobacillus acidophilus and bifidobacterium bifidum on rectal cell kinetics and fecal pH. G Biasco, GM Paganelli, G Brandi, S Brillanti, F Lami… - The Italian journal of gastroenterology, 1991 

Ano-rectal lesions in patients taking suppositories containing non-steroidal anti-inflammatory drugs (NSAID). G Gizzi, V Villani, G Brandi, GM Paganelli, G Di Febo… - Endoscopy, 1990

Rectal cell proliferation and colorectal cancer risk level in patients with nonfamilial adenomatous polyps of the large bowel GM Paganelli, G Biasco, R Santucci, G Brandi, AA Lalli… - Cancer, 1991 

Correlation between endoscopic features of gastric antrum, histology and Helicobacter pylori infection in adults. C Calabrese, G Di Febo, G Brandi, AM Morselli-Labate… - Italian journal of gastroenterology and …, 1998 

Changes in the surgical approach to hilar cholangiocarcinoma during an 18‐year period in a Western single center G Ercolani, M Zanello, GL Grazi, M Cescon, M Ravaioli… - Journal of hepato-biliary-pancreatic sciences, 2010

Colorectal cancer in patients with ulcerative colitis. A prospective cohort study in Italy          G Biasco, G Brandi, GM Paganelli, FP Rossini… - Cancer, 1995

Urease-positive bacteria other than Helicobacter pylori in human gastric juice and mucosa   G Brandi, B Biavati, C Calabrese, M Granata… - The American journal of gastroenterology, 2006 

Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice MA Pantaleo, A Astolfi, M Nannini, P Paterini, G Piazzi… - British journal of cancer, 2008

Intestinal microflora and digestive toxicity of irinotecan in mice. G Brandi, J Dabard, P Raibaud, M Di Battista… - Clinical cancer research, 2006

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers G Allegrini, T Di Desidero, MT Barletta, A Fioravanti… - Angiogenesis, 2012 

Lack of association with spondyloarthritis and HLA-B27 in Italian patients with Whipple's disease. I Olivieri, G Brandi, A Padula, M Di Stefano… - The Journal of rheumatology, 2001 

Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? MA Pantaleo, M Di Battista, F Catena, M Astorino… - Journal of cancer research and clinical …, 2008 

Bifidobacterium animalis protects intestine from damage induced by zinc deficiency in rats   E Mengheri, F Nobili, F Vignolini, M Pesenti, G Brandi… - The Journal of nutrition, 1999 

Neoadjuvant treatment in rectal cancer: actual status I Garajová, S Di Girolamo, F de Rosa, J Corbelli… - Chemotherapy research and practice, 2011 

Cancer surveillance in ulcerative colitis: critical analysis of long-term prospective programme G Biasco, FP Rossini, R Hakim, G Brandi, M Di Battista… - Digestive and Liver Disease, 2002 

Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases MA Pantaleo, M Nannini, E Lopci, P Castellucci… - International journal of oncology, 2008 

Chemoprevention of colorectal cancer: role of antioxidant vitamins. G Biasco, GM Paganelli, G Brandi, R Santucci, AA Lalli… - European Journal of Cancer Prevention, 1992 

Cold single-strand conformation polymorphism analysis: optimization for detection of APC gene mutations in patients with familial adenomatous polyposis P Strippoli, S Sarchielli, R Santucci, GP Bagnara… - International journal of molecular medicine, 2001 

Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer G Brandi, C Calabrese, MA Pantaleo, AM Labate… - Cancer letters, 2004 

Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study    G Brandi, F De Rosa, V Agostini, S Di Girolamo… - The oncologist, 2013

To widen the setting of cancer patients who could benefit from metronomic capecitabine       M Nannini, E Nobili, R Di Cicilia, G Brandi, A Maleddu… - Cancer chemotherapy and pharmacology, 2009

Cell renewal and cancer risk of the stomach: analysis of cell proliferation kinetics in atrophic gastritis. G Biasco, GM Paganelli, S Brillanti, AA Lalli, G Brandi… - Acta gastro-enterologica Belgica, 1988 

Activated NF-kB in colorectal cancer: predictive or prognostic factor? G Brandi, MA Pantaleo, G Biasco, P Paterini - Journal of Clinical Oncology, 2008 

Cell proliferation and ultrastructural changes of the duodenal mucosa of patients affected by familial adenomatous polyposis G Biasco, G Cenacchi, E Nobili, MA Pantaleo… - Human pathology, 2004

Durable complete response of hepatocellular carcinoma after metronomic capecitabine          G Brandi, F de Rosa, L Bolondi, V Agostini… - Tumori, 2010

Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations G Brandi, S Tavolari, F De Rosa, S Di Girolamo… - PloS one, 2012

Port a Cath related complications in 252 patients with solid tissue tumours and the first report of heparin‐induced delayed hypersensitivity after Port a Cath... I Garajová, G Nepoti, M Paragona, G Brandi, G Biasco - European journal of cancer care, 2013

Impact of surgery on the development of duodenal cancer in patients with familial adenomatous polyposis G Biasco, E Nobili, C Calabrese, R Sassatelli… - Diseases of the colon & rectum, 2006 

Methodological problems in the use of rectal cell proliferation as a biomarker of colorectal cancer risk. G Biasco, GM Paganelli, R Santucci, G Brandi… - Journal of cellular biochemistry. Supplement, 1993

Discrepancy between declared and recovered bifidobacteria in a human probiotic   P Mattarelli, G Brandi, M Modesto, B Biavati - Annals of microbiology, 2002

Exocrine-Endocrine Pancreatic Cancer and α-Fetoprotein G Brandi, E Nobili, E Capizzi, B Corti, R Di Cicilia… - Pancreas, 2008 

Abnormal rectal cell proliferation and p52p35 protein expression in patients with ulcerative colitis GM Paganelli, PJ Higgins, G Biasco, M Lipkin, G Brandi… - Cancer letters, 1993 

Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis G Brandi, S Di Girolamo, A Farioli, F de Rosa, S Curti… - Cancer Causes & Control, 2013

Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases G Ercolani, A Cucchetti, M Cescon, E Peri, G Brandi… - European Journal of Cancer, 2011 

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer L Fornaro, S Cereda, G Aprile, S Di Girolamo, D Santini… - British journal of cancer, 2014 

ANALYSIS OF ILEAL BACTERIAL-FLORA IN PATIENTS WITH ILEAL-ANAL ANASTOMOSIS WITH AND WITHOUT POUCHITIS G Brandi, S Chaussade, M Ladire, J Nicoli… - Gut, 1992

Correlation between bromodeoxyuridine labelling and ornithine decarboxylase levels in normal rectal mucosa of patients with colorectal adenoma GM Paganelli, G Saccoccio, G Brandi, S Bellentani… - Cancer letters, 1991

Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients G Brandi, M Nannini, MA Pantaleo, S Fanello… - Chemotherapy, 2008 

Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience E Nobili, R Di Cicilia, M Di Battista, AM Morselli-Labate… - Pathophysiology of haemostasis and …, 2009 

Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases G Brandi, E Derenzini, A Falcone, G Masi, F Loupakis… - Clinical colorectal cancer, 2013 

HIV enteropathy: undescribed ultrastructural changes of duodenal mucosa and their regression after triple antiviral therapy. A case report G Brandi, C Calabrese, R Manfredi, AM Pisi, G Di Febo… - Digestive diseases and sciences, 2005 

A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma G Brandi, G Biasco, MG Mirarchi, R Golfieri, A Di Paolo… - Digestive and Liver Disease, 2011 

Flow cytometry and in vitro tritiated thymidine labeling in normal rectal mucosa of patients at high risk of colorectal cancer. GM Paganelli, E Lalli, A Facchini, G Biasco, R Santucci… - The American journal of gastroenterology, 1994

Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)(quadrupleWT, or KITWT/PDGFRAWT/SDHWT/RAS-PWT GIST) M Nannini, A Astolfi, M Urbini, V Indio, D Santini… - BMC cancer, 2014 

Bacteria in biopsies of human hypochloridric stomach: a scanning electron microscopy study G Brandi, A Pisi, G Biasco, M Miglioli, B Biavati… - Ultrastructural pathology, 1996 

Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine G Brandi, MA Pantaleo, C Calabrese, M Di Battista… - International journal of colorectal disease, 2004 

Metronomic capecitabine in advanced patients with hepatocellular carcinoma (HCC): Preliminary results G Brandi, S Fanello, F Piscaglia, A Falanga, L Bolondi… - ASCO Annual Meeting Proceedings, 2007 

Esposizione all'amianto in pazienti affetti da neoplasie delle vie biliari Asbestos exposure in patients affected by bile duct tumours G Brandi, S Di Girolamo, F Belpoggi, G Grazi… - Eur. J. Oncol, 2008 

Rectal cell proliferation as an intermediate biomarker of risk of colorectal cancer.G Biasco, GM Paganelli, G Brandi, R Santucci… - European journal of cancer prevention, 1993 

Second-line chemotherapy in patients with biliary tract cancer. G Brandi, S Di Girolamo, F De Rosa, J Corbelli… - ASCO Annual Meeting Proceedings, 2011

Unresectable perihilar cholangiocarcinoma: multimodal palliative treatment C Mosconi, M Renzulli, E Giampalma, A Galuppi… - Anticancer research, 2013 

Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?     G Brandi, F Rosa, L Calzà, SD Girolamo, M Tufoni… - Liver International, 2013 

Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy? G Brandi, M Venturi, E Dika, H Maibach, A Patrizi… - Cutaneous and ocular toxicology, 2013

Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases G Brandi, J Corbelli, F de Rosa, S Di Girolamo… - Langenbeck's Archives of Surgery, 2012 

Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms? G Brandi, F de Rosa, R Danesi, GC Montini, G Biasco - European urology, 2008 

Gene expression profiling differences between synchronous and metachronous liver metastases of colorectal cancer MA Pantaleo, A Astolfi, M Nannini, G Ercolani, G Brandi… - Molecular Cancer Therapeutics, 2007 

Irinotecan toxicity: genes or intestinal microflora? G Brandi, F de Rosa, G Biasco - British journal of cancer, 2009

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24–25 June 2014, Milan G Bouche, N André, S Banavali, F Berthold, A Berruti… - ecancermedicalscience, 2014

[Treatment of colorectal cancer liver metastases] E Derenzini, M Di Battista, MC Di Marco, S Dell'Arte… - Minerva medica, 2006

Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects A Patrizi, M Venturi, E Dika, H Maibach, P Tacchetti… - Cutaneous and ocular toxicology, 2014

Synbiotic yogurt consumption by healthy adults and the elderly: the fate of bifidobacteria and LGG probiotic strain M Granata, G Brandi, A Borsari, R Gasbarri, DD Gioia - International journal of food sciences and …, 2013 

Risk of duodenal cancer in patients with familial adenomatous polyposis G Biasco, MA Pantaleo, G Di Febo, C Calabrese… - Gut, 2004

Is there a relationship between hypergastrinemia and colorectal cancer risk? Rectal cell proliferation in Zollinger-Ellison syndrome. G Biasco, G Brandi, M Renga, GM Paganelli… - The American journal of gastroenterology, 1995

CS. 01.3 THE EMERGING IMPACT OF HCC-NAFLD IN ITALY S Bellentani, A Barchetti, E Dionigi, A Fracanzani… - Digestive and Liver Disease, 2012

THE RELATIONSHIP BETWEEN TYPE-A AND TYPE-B GASTRITIS AND HELICOBACTER-PYLORIG Biasco, GM Paganelli, R Santucci, G Brandi… - EUROPEAN JOURNAL OF …, 1993

The emerging role of 3D and 2D contrast-enhanced ultrasound with quantitative analysis in evaluating the response to new antitumoral treatments C Serra, G Brandi - Medicamundi, 2007 

Occurrence of Bifidobacteriaceae in human hypochlorhydria stomach P Mattarelli, G Brandi, C Calabrese, F Fornari, GM Prati… - Microbial ecology in health and disease, 2014 

Metronomic capecitabine as second-line treatment for patients with hepatocellular carcinoma with preserved liver function: A phase II study. F De Rosa, V Agostini, S Di Girolamo, P Andreone… - ASCO Annual Meeting Proceedings, 2011

Systemic adjuvant chemotherapy after resection of colorectal cancer metastases G Brandi, E Derenzini, MA Pantaleo, M Di Battista… - ANNALS OF ONCOLOGY, 2004 

Mutagenic and clastogenic activity of gastric juice in human gastric diseases P Hrelia, C Fimognari, F Maffei, G Brandi, G Biasco… - Mutation Research/Genetic Toxicology and …, 2002 

CASE REPORT: Severe and Relapsing Upper Gastrointestinal Bleeding in a Patient with Glanzmann's Thrombasthenia C Calabrese, G Di Febo, A Areni, MC Morelli, C Scialpi… - Digestive diseases and sciences, 2000 

Antiprotease Strategy in Pancreatic Cancer Treatment: Emergence From a Preclinical Study G Brandi, S Tavolari, T Guarnieri, M Di Marco… - Pancreas, 2014

Cell kinetics of the gastric mucosa of patients treated with omeprazole. G Biasco, P Mordenti, G Brandi, GM Paganelli… - The American journal of gastroenterology, 1996 

Safety of hepatic resection for colorectal metastases in the era of neo-adjuvant chemotherapy A Cucchetti, G Ercolani, M Cescon, P Di Gioia, E Peri… - Langenbeck's Archives of Surgery, 2012 

Second-line chemotherapy in advanced biliary cancer: the present now will later be past        C Vivaldi, L Fornaro, S Cereda, G Aprile, D Santini… - Annals of Oncology, 2014

Is adjuvant systemic chemotherapy after resection of metastases from colorectal cancer suitable? MA Pantaleo, G Brandi, E Derenzini, S Fanello… - ASCO Annual Meeting Proceedings, 2004

Bacterial colonization in juice and biopsies of the achlorhydric stomach G Brandi, G Biasco, B Biavati, GM Paganelli, C Masci… - Gastroenterology, 1995

Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases M Di Marco, M Macchini, S Vecchiarelli, R Casadei… - Oncology letters, 2011

Preliminary results of metronomic capecitabine treatment in advanced hepatocellular carcinoma (HCC) G Brandi, S Fanello, F Piscaglia, A Falanga, D Balducci… - ANNALS OF ONCOLOGY, 2007 

GEMOX as first-line chemotherapy in advanced pancreatic cancer (APC): A monoinstitutional experience M Di Marco, E Nobili, R Di Cicilia, G Brandi, S Bertolini… - ASCO Annual Meeting Proceedings, 2007

Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations G Brandi, G Biasco, S Tavolari - Journal of the National Cancer Institute, 2011 

Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC) G Brandi, P Paterini, S Tavolari, G Da Pozzo, E Nobili… - ASCO Annual Meeting Proceedings, 2009

Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma. S Di Girolamo, E Nobili, E Derenzini, F de Rosa… - ASCO Annual Meeting Proceedings, 2011 

Bifidobacteria: Microbiological Aspects and Probiotic Potentialities G Brandi, B Biavati, G Biasco - 2003

Risk of duodenal adenomas in familial adenomatous polyposis to progress toward advanced neoplastic disease G Biasco, MA Pantaleo, G Di Febo, C Calabrese… - Journal of clinical oncology, 2004

Dose response effects of 2-acetylaminofluorene on DNA damage, cytotoxicity, cell proliferation and neoplastic conversion in rat liver T. Umemura, K. Tokumo, H. Sirma, R.... Y Kataoka, T Matsumura, S Yamamoto, T Sugimoto… - Cancer Letters, 1993

Triple therapy with azithromycine, lansoprazole and tinidazole is highly effective in the eradication of Helicobacter pylori: A pilot (open) study G DiFebo, C Calabrese, G Brandi, A Areni, A Muia… - GUT, 1997

Eparine a basso peso molecolare e sopravvivenza in pazienti con cancro. Selezione di casi e revisione della letteratura Low molecular weight heparins and survival in cancer...G Brandi, S Di Girolamo, V Agostini, R Di Cicilia… - Eur. J. Oncol, 2008 

Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): a multicenter case-control study F Piscaglia, GS Baroni, A Barchetti, A Pecorelli… - Digestive and Liver Disease, 2015

News| ForumNO Witherspoon, E Janus, MT Martin, DJ Dix, G Brandi…

Liver metastases from colorectal cancer G Biasco, E Derenzini, S Fanello, G Brandi - EUROPEAN JOURNAL OF ONCOLOGY, 2005 

20 P Omeprazole therapy induce the ultrastructural healing in acid reflux oesophagitis. A preliminary report C Calabrese, M Bortolotti, A Fabbri, A Areni… - Digestive and Liver Disease, 2002 

Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment M Macchini, G Brandi, S Tavolari, T Guarnieri… - Pancreatology, 2012

Phase I/II trial of continuous hepatic arterial infusion (HAI) of Irinotecan in patients with hepatocellular carcinoma (HCC). Preliminary results M Pantaleo, E Derenzini, F Piscaglia, R Golfieri… - ASCO Annual Meeting Proceedings, 2006

Impact of surgery and chemotherapy on survival in cholangiocarcinoma G Brandi, E Derenzini, E Nobili, MC Di Marco… - ANNALS OF ONCOLOGY, 2005 

Follow-up in oncologia G Brandi, G Biasco - 2015

Effect of folate and a-lipoic acid supplementation on rectal mucosal cell kinetics M Di Marco, R Di Cicilia, M Di Battista, G Brandi… - ANNALS OF ONCOLOGY, 2006

High prevalence of asbestos exposure in bile duct cancer patients. S Di Girolamo, F de Rosa, E Nobili, V Agostini… - ASCO Annual Meeting Proceedings, 2010 

Some pathological features of Giardia infecting the human small intestine observed at SEM A Pisi, G Brandi, G Filippini, G Biasco, C Calabrese…

Correspondence-in-Press E Janus, G Brandi, E Nobili, SD Girolamo, G Grazi… 

METRONOMIC CAPECITABINE IN HEPATOCELLULAR CARCINOMA RELAPSE AFTER LIVER TRANSPLANTATION: A RETROSPECTIVE STUDY F de Rosa, V Agostini, M Ravaioli, M Cescon, GL Grazi… - ANNALS OF ONCOLOGY, 2009

Preliminary report on a phase I/II trial of continuos hepatic arterial infusion (HAI) of irinotecan (CPT-11) in patients (PTS) with locally advanced hepatocellular carcinoma (HCC) F Piscaglia, MG Mirarchi, E Derenzini, A Lanzi… - HEPATOLOGY, 2006

Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors MA Pantaleo, A Astolfi, M Urbini, F Fuligni, M Saponara… - Clinical sarcoma research, 2014

Gene expression profiling of liver metastases from colorectal cancer: differences between synchronous and metachronous lesions MA Pantaleo, A Astolfi, M Nannini, P Paterini, G Piazzi… - ASCO Annual Meeting Proceedings, 2008 

The Best Management of Portal Neoplastic Thrombosis in Hepatocellular Carcinoma             G Brandi, S De Lorenzo, M Venturi, J Corbelli, G Frega… - 2014

Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK)... G Allegrini, G Bocci, M Barletta, A Fioravanti… - ANNALS OF ONCOLOGY, 2008 

Low molecular weight heparins and survival in cancer patients. Case collection and review of the literature G Brandi, S Di Girolamo, V Agostini, R Di Cicilia - European Journal of Oncology, 2008

Carboplatin (CBDCA) and paclitaxel (TAX) as induction chemotherapy in stage IIIA–IIIB in non small cell lung cancer (NSCLC) S Tamberi, E Gallerani, R Bazzocchi, M Zompatori… - European Journal of Cancer, 1999 

Extrahepatic Feeding of HCC Limits the Use of TACE? Evidences from Literature and Clinical Experience A Tovoli, L Napoli, M Mastroroberto, M Renzulli… - 2013 

Il trattamento delle metastasi epatiche da cancro del colon-retto E Derenzini, M Di Battista, MC Di Marco, S DELL'ARTE… - Minerva medica, 2006

THE PROTEASE INHIBITOR GABEXATE MESYLATE HAS ANTI-TUMOR EFFECTS AND ENHANCES GEMCITABINE ACTION ON PANCREATIC CANCER CELL LINES G Brandi, S Tavolari, P Paterini, F de Rosa… - ANNALS OF ONCOLOGY, 2009 

Familial adenomatous polyposis (FAP): Dysplasia and pouchitis of the pouch after ileal pouch-anal anastomosis (IPAA) C Calabrese, G Di Febo, A Areni, E Nobili, G Brandi… - Gastroenterology, 2000

Endoscopy fails in identifying the presence of Helicobacter pylori (Hp) in gastric antrum of adults G Di Febo, C Calabrese, G Brandi, AM Morselli-Labate… - Gastroenterology, 1998 

Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness F Vasuri, L Rocchi, A Degiovanni, F Giunchi, G Brandi… - Histopathology, 2015

Phase I/II trial of continuous hepatic arterial infusion (HAI) of irinotecan in patients with hepatocellular carcinoma (HCC). Preliminary results G Brandi, E Derenzini, MA Pantaleo, F Piscaglia… - ANNALS OF ONCOLOGY, 2006 

BACTERIAL-FLORA OF THE ILEAL RESERVOIR AFTER ILEAL-ANAL ANASTOMOSIS IN PATIENTS WITH AND WITHOUT POUCHITIS G Brandi, S CHAUSSADE, M LADIRE, J NICOLI… - GASTROENTEROLOGY, 1993 

The Editors wish to thank the following individuals who have assisted the Journal of Chemotherapy in 2009 with the critical task of reviewing and screening articles submitted...  D Adam, C Adembri, L Aguilar, G Amicosante… 

KRAS and BRAF mutational status as selective criteria for targeted therapy in cholangiocarcinoma. G Brandi, M Fiorentino, S Di Girolamo, F de Rosa… - ASCO Annual Meeting Proceedings, 2010 

Colorectal Cancer in Patients with Ulcerative Colitis G Biasco, G Brandi, GM Paganelli, FP Rossini…

Breast carcinoma presenting as linitis plastica G Brandi, E Campadelli, E Nobili, O Leone - Digestive and Liver Disease, 2010 

Second-line chemotherapy for advanced biliary tract cancer: Results of a multicenter surveyE Vasile, S Di Girolamo, S Cereda, S Lonardi, F Leone… - EUROPEAN JOURNAL OF CANCER, 2013

Cancer Letters, Vol. 60, No. i, October 1991 C Fernandes, KVK Rao, GM Paganelli, G Saccoccio… - Toxicology, 1991 

The risk of duodenal cancer in familial adenomatous polyposis (FAP) G Biasco, R Sassatelli, E Nobili, L Camellini… - ANNALS OF ONCOLOGY, 2005

Colite ulcéreuse chronique et cancer colorectal G Biasco, GM Paganelli, G Brandi, M Miglioli… - Acta endoscopica, 1995

IMPACT OF MULTIDISCIPLINARY APPROACH ON SURVIVAL OF PATIENTS WITH KLATSKIN TUMOR S Di Girolamo, V Agostini, E Nobili, F De Rosa… - ANNALS OF ONCOLOGY, 2009

Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutics Targets for Tyrosine Kinase Inhibitors G Brandi, S Tavolari, G Biasco - Gastroenterology, 2012

21 P Dilated intercellular spaces of human oesophageal epithelium as the first and most sensitive marker of damage in acid reflux oesophagitis C Calabrese, M Bortolotti, A Fabbri, A Areni… - Digestive and Liver Disease, 2002 

After surgery surveillance in high risk colorectal cancer patients R Santucci, B Poggi, L Volpe, C Calabrese, P Mordenti… - ANNALS OF ONCOLOGY, 1998 

Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients.            G Brandi, S Tavolari, F Vasuri, A Farioli, M Deserti… - JOURNAL OF CLINICAL ONCOLOGY, 2013 

Gastrointestinal stromal tumors: A monoinstitutional experience M Di Battista, MA Pantaleo, M Astorino, G Brandi… - ASCO Annual Meeting Proceedings, 2007 

Lipohyperplasia of the ileocecal valve. Description of 7 cases M Ricci, G Mazzoleni, G Brandi, MC Celli, R Zendron… - Minerva chirurgica, 1988 

COLORECTAL-CANCER IN ULCERATIVE-COLITIS-A PROSPECTIVE COHORT STUDY IN ITALY G BIASCO, G BRANDI, GM PAGANELLI, FP ROSSINI… - GASTROENTEROLOGY, 1994 

Phase II study of temozolomide and celecoxib in the treatment of metastatic melanoma R Hakim, R Poggi, M Pantaleo, G Benedetti, G Brandi… - ASCO Annual Meeting Proceedings, 2006

Chronic ulcerative colitis and colorectal cancer G Biasco, GM Paganelli, G Brandi, M Miglioli - ACTA ENDOSCOPICA, 1995 

Biomarkers of genetic activity in the study of achlorhydric stomach F Vigagni, P Hrelia, F Maffei, G Biasco, G Brandi… - Pharmacology and Toxicology-Supplements, 1995

Adamson, RH Agarwal. R. Agarwal, SC 135 Aitken. A. M Azuma, M Imoto, A Inoue, M Ishikawa, D Ivanyi… 

Multivariate prognostic factor analysis in patients (pts) with advanced biliary tract cancer (aBTC) treated with second-line chemotherapy (CT) L Fornaro, S Cereda, F Bergamo, F Leone, M Russano… - EUROPEAN JOURNAL OF CANCER, 2013 

Antiprotease Strategy in Pancreatic Cancer Treatment G Brandi, S Tavolari, T Guarnieri… - 2013 

Measurement of rectal cell proliferation by bromodeoxyuridine uptake and proliferating cell nuclear antigen (PCNA). GM Paganelli, G Biasco, R Santucci, G Brandi, AA Lalli… - European Journal of Cancer Prevention, 1993 

Intestinal Microbiota around Colorectal Cancer Genesis G Brandi, F De Rosa, G Liguori, V Agostini… 

Occupational exposure to asbestos and cholangiocarcinoma: findings from an explorative case-control analysis G Brandi, A Farioli, S Di Girolamo, S Curti, F De Rosa… - Occupational and Environmental Medicine, 2011 

OC-26 The emerging impact of HCC-NAFLD in Italy S Bellentani, A Brachetti, E Dionigi, A Fracanzani… - Digestive and Liver Disease, 2012 

Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. G Brandi, S De Lorenzo, S Di Girolamo, S Bellentani… - Tumori, 2014

Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S - Oncotarget, 2015

Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma. Minichillo S, Pantaleo MA, Nannini M, Coccolo F, Gatto L, Biasco G, Brandi G - BMC Res Notes, 2015

Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). Astolfi A, Urbini M, Indio V, Nannini M, Genovese CG, Santini D, Saponara M, Mandrioli A, Ercolani G, Brandi G, Biasco G, Pantaleo MA - BMC Genomics, 2015

Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn's Disease Patients. Liguori G, Lamas B, Richard ML, Brandi G, da Costa G, Hoffmann TW, Di Simone MP, Calabrese C, Poggioli G, Langella P, Campieri M, Sokol H - J Crohns Colitis, 2016

Estimation of the Survival Benefit Obtainable From Screening for the Early Detection of Pancreatic Cancer. Cucchetti A, Ercolani G, Cescon M, Brandi G, Taffurelli G, Maroni L, Ravaioli M, Pezzilli R, Pinna AD - Pancreas, 2016

Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma? Renzulli M, Brocchi S, Cucchetti A, Mazzotti F, Mosconi C, Sportoletti C, Brandi G, Pinna AD, Golfieri R - Radiology, 2016

Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center. Brandi G, Venturi M, Pantaleo MA, Ercolani G; GICO - Dig Liver Dis, 2016

Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall'Olio FG, Barbera MA, Pantaleo MA, Biasco G - World J Gastroenterol, 2016

Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. Brandi G, Deserti M, Vasuri F, ...; G.I.CO. (Gruppo Italiano Colangiocarcinoma) - Oncologist, 2016

Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Mosconi C, Gramenzi A, Ascanio S, Cappelli A, Renzulli M, Pettinato C, Brandi G, Monari F, Cucchetti A, Trevisani F, Golfieri R - Br J Cancer, 2016

Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention. Brandi G, De Lorenzo S, Palloni A, Biasco G, Tovoli F - Hepatology, 2017

Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies. Marinelli I, Guido A, Fuccio L, Farioli A, Panni V, Giaccherini L, Arcelli A, Ercolani G, Brandi G, ... Anticancer Res, 2017

Microbiota, NASH, HCC and the potential role of probiotics. Brandi G, De Lorenzo S, Candela M, Pantaleo MA, Bellentani S, Tovoli F, Saccoccio G, Biasco G - Carcinogenesis, 2017

 

Istituto di Ematologia ed Oncologia Medica                             

“L.A. Seragnoli” Policlinico Sant'Orsola-Malpighi                         

tel 051 2143838                                             

fax 051 2144037

email: giovanni.brandi@unibo.it